Pharmaceutical industry

Cutera® Celebrates One Year of Revolutionizing the Acne Market with AviClear® During Acne Awareness Month

Retrieved on: 
Thursday, June 1, 2023
Luxury, Medical Devices, Other Retail, Specialty, Practice Management, Other Health, Health, Cosmetics, Retail, Senior, Acne, Multimedia, Research, Dermatology, Publication, Patient, Gland, FDA, Global marketing, Pharmaceutical industry

CUTERA, INC. (Nasdaq: CUTR) a global leader in aesthetic and dermatology solutions, today celebrates the start of Acne Awareness Month and a year since the unveiling of AviClear , the first FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne.

Key Points: 
  • CUTERA, INC. (Nasdaq: CUTR) a global leader in aesthetic and dermatology solutions, today celebrates the start of Acne Awareness Month and a year since the unveiling of AviClear , the first FDA-cleared energy-based device for the treatment of mild, moderate, and severe acne.
  • Engineered with all skin types in mind, the AviClear laser selectively targets and suppresses the sebaceous glands, eliminating acne at the source, providing a durable solution to acne.
  • "Cutera’s recent 12-month data further confirms what I have observed with my patients – AviClear is a highly effective, non-invasive treatment option for acne that truly delivers long-term results."
  • We are excited to continue positively affecting the lives of acne sufferers in the years to come.”
    To learn more about AviClear, please visit AviClear’s website , TikTok and Instagram .

Cybin to Present at the Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 1, 2023
Mental Health, Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Webcast, Inc., Conference, NYSE, Event, NEO, Pharmaceutical industry, Broadcasting

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York City, NY from June 7-9, 2023.

Key Points: 
  • Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the Jefferies Healthcare Conference taking place in New York City, NY from June 7-9, 2023.
  • Mr. Drysdale’s presentation will be webcast live on Friday, June 9, 2023 at 8:00 a.m.
  • To listen to the event, please click here to access the webcast.
  • The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.

Xeris Biopharma to Participate at the Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Webcast, Conference, Eastern Time Zone, Pharmaceutical industry, Broadcasting, Life insurance

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time.

Key Points: 
  • Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that members of its senior management will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 8 at 10:30am Eastern Time.
  • A live webcast of the event will be available on the 'Events & Presentations' section of Xeris’ Investor Relations website at https://xerispharma.com/investor-relations or https://wsw.com/webcast/jeff281/xers/1879020 .
  • A replay of the webcast will be available for 60 days.

Switch Therapeutics Announces Formation of Scientific Advisory Board

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Pharmaceutical, Health, Carbon, Tissue, Amgen, University of Bristol, University of East London, Migraine, University, Senior, Doctor of Philosophy, Schizophrenia, CSO, P. R. Mallory and Co Inc, Western University, Rochester, Thomas Jefferson University, Pulsus Group, Nitric oxide, Coronavirus Scientific Advisory Board, DRS, Janssen, Physiology, Research, Iron monosilicide, Johns Hopkins School of Medicine, RNA, Genentech, Princeton University, Drexel University, CNS, Conditional, Pain, Discovery, Lilly, Molecular neuroscience, Outline of health sciences, Novo Nordisk, RNA interference, Merck, Therapy, Oligonucleotide, Western University of Health Sciences, Disease, Research fellow, Pharmaceutical industry, Erenumab, Neuroscience, Chemistry, Biology

Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.

Key Points: 
  • Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi (Conditionally Activated siRNA) platform, today announced the formation of its Scientific Advisory Board.
  • Marc Abrams, David Bredt and James Treanor to our company’s Scientific Advisory Board,” said Dee Datta, Ph.D., co-founder and CEO of Switch Therapeutics.
  • “Together, they bring decades of experience in CNS and RNA therapies and we’re thrilled for them to join the Switch Therapeutics team.
  • Dr. Abrams spent the first 17 years of his career at Merck and Co., Inc in scientific positions of increasing responsibility.

REALM IDx Launches REALM Pharma Services to Improve Drug Development and Research

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Artificial Intelligence, Genetics, Science, Clinical Trials, Drug development, CGP, Pathology, Cancer, Data collection, IDX, Genomics, Doctor of Philosophy, Norwich Pharma Services, American Society of Clinical Oncology, Machine learning, Drug discovery, Artificial intelligence, Society, Pharmaceutical industry, Medical imaging

REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.

Key Points: 
  • REALM IDx announced today the launch of REALM Pharma Services, an end-to-end discovery, translational research, and clinical trial service for biotechnology and pharmaceutical partners.
  • Through a strategic integration, REALM Pharma Services brings together the research arms of subsidiaries, Ambry Genetics and Invicro, to offer cutting-edge genomics, traditional and molecular pathology, and advanced imaging and spatial biology.
  • “In supporting our biopharma partners, we see ourselves as a powerful connecting force,” said Jonathan Usuaka, PhD, Chief Strategy and Informatics Officer for REALM IDx.
  • Additional information about REALM Pharma Services may be found on REALM’s website .

Boundless Bio to Present at the 2023 Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Genetics, Clinical Trials, Oncology, DNA, Therapy, Patient, Conference, Bio, A-DNA, Chief medical informatics officer, Pharmaceutical industry

Boundless Bio , a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City.

Key Points: 
  • Boundless Bio , a clinical stage, next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) for patients with oncogene amplified cancers, today announced that Chief Medical Officer, Klaus Wagner, M.D., Ph.D., will present at the 2023 Jefferies Healthcare Conference which will take place in New York City.
  • Presentation details are as follows:

Forbes Names CBRE One of America’s Net-Zero Leaders

Retrieved on: 
Thursday, June 1, 2023
Sustainability, Commercial Building & Real Estate, Construction & Property, Environment, CBRE Group, Morning Star, Risk management, EV, Sustainalytics, NYSE, Corporate social responsibility, CBRE, Corporation, Renewable energy, Pharmaceutical industry

CBRE Group, Inc. (NYSE:CBRE) has been named to Forbes’ inaugural Net-Zero Leaders list.

Key Points: 
  • CBRE Group, Inc. (NYSE:CBRE) has been named to Forbes’ inaugural Net-Zero Leaders list.
  • CBRE was the highest-ranked commercial real estate services company.
  • Forbes’ Net Zero Leaders list was created using data from research firms Sustainalytics and Morningstar.
  • “CBRE is driving measurable progress in lowering energy consumption in our own operations as well as the more than 7 billion square feet we manage for our clients globally.

MindMed to Participate at Upcoming Investor Conferences

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, NEO, Medicine, MindMed, Pharmaceutical industry

Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

Key Points: 
  • Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company’s management team will participate in the following investor conferences:

Veracity Appoints Dr. Taz Bhatia as First-Ever Chief Hormone Officer, Raising the Bar for the Beauty and Wellness Industry

Retrieved on: 
Thursday, June 1, 2023
Alternative Medicine, Health, Consumer, Women, Fitness & Nutrition, General Health, Vitamins, Supplements, Online, Exercise, Hormone, Diet, Today (American TV program), Alternative medicine, Sleep, Woman, Multimedia, Beauty, Metabolism, Public key certificate, Knowledge, Nutritionist, Female, Pharmaceutical industry, Birth control, Veracity

Veracity announces Dr. Taz Bhatia, M.D., as their Chief Hormone Officer and a member of Veracity’s Medical Advisory Board.

Key Points: 
  • Veracity announces Dr. Taz Bhatia, M.D., as their Chief Hormone Officer and a member of Veracity’s Medical Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20230601005251/en/
    Veracity partners with Dr. Taz to bring awareness to hormone health and wellness, helping more women look and feel their best.
  • (Photo: Business Wire)
    Veracity, the beauty and wellness brand rooted in hormone health, exists to help women to look and feel their best.
  • The appointment of Dr. Taz Bhatia, M.D., as Chief Hormone Officer is the latest step in realizing this mission, helping more women unlock the intricate connections between hormones and overall wellness.

Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

Retrieved on: 
Thursday, June 1, 2023
Biotechnology, Health, Oncology, Cancer, Conference, ACET, Bio, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 7-9, 2023 in New York.
  • Details of the event are as follows:
    The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com .
  • An archived replay will be available for 30 days following the presentation.